中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价

吴艳琴 沈黎俊 于集虹 孙玉山

引用本文:
Citation:

恩替卡韦治疗慢性乙型肝炎合并肝脂肪变的效果评价

DOI: 10.3969/j.issn.1001-5256.2017.05.011
基金项目: 

春雨工程感染科专项科研基金(2014-05); 

详细信息
  • 中图分类号: R512.62;R575

Clinical effect of entecavir in treatment of chronic hepatitis B complicated by hepatic steatosis

Research funding: 

 

  • 摘要:

    目的探讨慢性乙型肝炎(CHB)合并肝脂肪变患者经恩替卡韦抗病毒治疗后的效果。方法纳入新疆巴州人民医院2014年6月-2015年6月就诊的HBe Ag阳性CHB患者164例,根据肝小叶内肝脂肪变的肝细胞数占总肝细胞数的比例将其分为3组:脂肪变肝细胞占比<5%(对照组,89例),脂肪变肝细胞占比5%30%(a组,43例),脂肪变肝细胞占比>30%组(B组,32例)。患者均给予恩替卡韦治疗。检测患者治疗前和治疗后24、48周血清病毒学指标和肝功能指标变化。计量资料组间比较采用单因素方差分析,进一步两两比较采用Bonferroni法;计数资料组间比较采用χ2检验。结果肝脂肪变不影响恩替卡韦治疗24周时的病毒学应答(P>0.05),但恩替卡韦治疗48周时,B组HBe Ag阴转率(34.4%vs 60.2%)和HBV DNA阴转率(40.6%vs67.4%)均明显低于对照组,差异具有统计学意义(P值分别为0.012和0.008);恩替卡韦治疗24和48周时,A组、B组的ALT复常率明显低于对照组,差异均有统计学意义(A组:P值分别为0....

     

  • [1]BOONSTRA A, WOLTMAN AM, JANSSEN HL.Immunology o hepatitis B and hepatitis C virus infections[J].Best Pract Res Clin Gastroenterol, 2008, 22 (6) :1049-1061.
    [2]PENG D, HAN Y, DING H, et al.Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J].J Gastroenterol Hepatol, 2008, 23 (7 Pt 1) :1082-1088.
    [3]MACHADO MV, OLIVEIRA AG, CORTEZ-PINTO H.Hepatic steatosis in hepatitis B virus infected patients:meta-analysis of risk factors and comparison with hepatitis C infected patients[J].J Gastroenterol Hepatol, 2011, 26 (9) :1361-1367.
    [4]SHI JP, FAN JG, WU R, et al.Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J].J Gastroenterol Hepatol, 2008, 23 (9) :1419-1425.
    [5]LIU SE, HAO MN, REN YN, et al.Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response[J].Chin J Hepatol, 2015, 23 (5) :333-338. (in Chinese) 刘淑娥, 郝美娜, 任亚楠, 等.慢性乙型肝炎患者合并脂肪肝导致单纯抗病毒治疗生物化学应答不佳诊疗分析[J].中华肝脏病杂志, 2015, 23 (5) :333-338.
    [6]CINDORUK M, KARAKAN T, UNAL S.Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection[J].J Clin Gastroenterol, 2007, 41 (5) :513-517.
    [7] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
    [8]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.
    [9]KIM KH, SHIN HJ, KIM K, et al.Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ[J].Gastroenterology, 2007, 132 (5) :1955-1967.
    [10]ZHENG RD, CHEN JN, ZHUANG QY, et al.Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis[J].Int J Med Sci, 2013, 10 (5) :641-646.
    [11]ZHENG RD, XU CR, JIANG L, et al.Predictors of hepatic steatosis in HBe Ag-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis[J].Int J Med Sci, 2010, 7 (5) :272-277.
    [12]ATES F, YALNIZ M, ALAN S.Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B[J].World J Gastroenterol, 2011, 17 (40) :4517-4522.
    [13]SHI JP, LU L, QIAN JC, et al.Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B[J].Chin J Hepatol, 2012, 20 (4) :285-288. (in Chinese) 施军平, 陆璐, 钱建成, 等.肝脂肪变对慢性乙型肝炎患者聚乙二醇干扰素α治疗临床疗效的影响[J].中华肝脏病杂志, 2012, 20 (4) :285-288.
    [14]JIN X, CHEN YP, YANG YD, et al.Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B[J].PLo S One, 2012, 7 (3) :e34198.
    [15]LECLERCQ I, HORSMANS Y, DESAGER JP, et al.Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation[J].JHepatol, 1998, 28 (3) :410-416.
    [16]WU L, PAREKH VV, GABRIEL CL, et al.Activation of invariant natural killer T cells by lipid excess promotes tissue inflammation, insulin resistance, and hepatic steatosis in obese mice[J].Proc Nati Acad U S A, 2012, 109 (19) :e1143-e1152.
    [17]KANURI G, LADURNER R, SKIBOVSKAYA J, et al.Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease[J].Liver Int, 2015, 35 (2) :562-568.
  • 加载中
计量
  • 文章访问数:  2709
  • HTML全文浏览量:  51
  • PDF下载量:  414
  • 被引次数: 0
出版历程
  • 出版日期:  2017-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回